
Urologist, MD, FEBU, Associate Professor, University Hospital Bern, @IBCN1979 Board Member, @EAUYAUrology Urothelial Cancer
Bern, Schweiz
Joined September 2016
- Tweets97
- Following186
- Followers353
- Likes149
Roland Seiler-Blarer retweeted
Excellent Day 1 of #IBCN2024. Great talks spanning Urothelial biology to using PDOs for therapy screening (and all biology in between). On to Day 2!
Roland Seiler-Blarer retweeted
Only 24hrs until #IBCN2024 with a record number of attendees! Looking forward to an incredible lineup of speakers and great scientific program.
ibcnweb.com/program_2024/
@pcvblack @LDyrskjot @mouwlab @ttodenhoefer @Roland3097 @jdamrauer
Can we make use of our organoid pipeline to precise treatment selection of NMIBC patients? Excited to conduct the GAIN-INST trial with a great scientific-clinical team @MariannKruithof @AbtDominik @je_bla @martademenna #SpitalzentrumBiel @unibern
rdcu.be/dbW79
What an honorable loss for our team @AbtDominik @je_bla 🍾👍Marco Sieber became enrolled as career astronaut at @ESA_de🚀.
Roland Seiler-Blarer retweeted
Replying to @Markuseckstein3
@Markuseckstein3 on bladder tumor subtype commitment occurring in CIS driven by key signaling pathways including ECM remodeling - may this observation be attributed to certain levels of tumor scarring? @Uroweb #EAU21 Also, great job by @JoshMeeks and @Roland3097 on the hosting! – at Rotterdam, The Netherlands
It’s a pleasure and honor being part of this group!
This Post is from an account that no longer exists. Learn more
Roland Seiler-Blarer retweeted
Different #BladderCancer Genotypes: New treatment options. #EAU20 presentation by @Roland3097 @unibern. Written coverage by @GoldbergHanan @UpstateNews on UroToday > bit.ly/3eH6hLl @Uroweb
Roland Seiler-Blarer retweeted
Conclusions and considerations of Assoc. Prof. @joostboormans's lecture "PD-1/PD-L1 Inhibitors are replacing perioperative chemotherapy" #EAU20
Roland Seiler-Blarer retweeted
A break on summer off for attending #eau20 and exchanging experiences in #bladdercancer. Great job of @uroweb allowing us to met virtually on #covi̇d19 era! Thanks!!!
Roland Seiler-Blarer retweeted
We’ve decided to hold our annual IBCN meeting ‘virtual’ on Saturday Oct 17th, 2020 starting at 1500 CET featuring keynote speakers @Dan_Theodorescu and Francois Radvanyi. Submit your abstracts before August 1. Further details including registration link coming soon!
Roland Seiler-Blarer retweeted
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
@Roland3097 @OncoBellmunt @Uromigos @pcvblack
#VisualAbstract #bladdercancer
europeanurology.com/article/…
Roland Seiler-Blarer retweeted
It was a pleasure to host the #IBCN2019 meeting in Aarhus and see so many friends and colleagues here. A meeting packed with so many great talks and poster presentations- and good discussions. Looking forward to #IBCN2020 @IBCN1997 @UroDocAsh @pcvblack @Roland3097 @ttodenhoefer
Thanks to everyone @pcvblack @daviesbj @mdallera @dr_coops @SimaPorten @ahmostafid @siemensr @carme_mir1 for having a great #URS19 in Bern. Have a good night and save travels back home!
Roland Seiler-Blarer retweeted
Replying to @MaxKates @JamesJmm23 @ColumbiaUrology @JohnsHopkins @eugene_pietzak @bbmdmsk @FaltasLab @JCensits @DSolit @djmcconkey @h_alahmadie
Hope you all can also make it to #IBCN2019 meeting in Arhaus this year @LDyrskjot @pcvblack @SWilliams_MD @Roland3097
Roland Seiler-Blarer retweeted
Now accepting abstracts for the 2019 Annual IBCN meeting
October 3 – 5, 2019 in Aarhus, Denmark. Abstract Deadline: July 1st, 2019. Please visit ibcnweb.net/upcoming-meeting… for abstract submission information. #IBCN2019 @pcvblack @UroDocAsh @Roland3097 @SWilliams_MD
Roland Seiler-Blarer retweeted
True honor to share my thoughts at the Plenary session #EAU19 @Uroweb with outstanding colleagues @UroDocAsh @PGrivasMDPhD @Roland3097 @SanRaffaeleMI @IstTumori
Roland Seiler-Blarer retweeted
Beyond #BCG in #BladderCancer #EAU19 going on now in eURO Auditorium 1 @MRoupret @Roland3097 @Uroweb @AndreaNecchi @EurUrolOncol @B_C_A_N @urotoday
































